All In Biotech

Drug Trial Radar · NCT06674694

The Purpose of This Study is to Determine the Safety, Tolerability, and Pharmacokinetics of Brexpiprazole Long-acting Injection Following a Single Administration in Healthy Subjects/Patients With Schizophrenia.

A Phase I Clinical Study of the Safety, Tolerability, and Pharmacokinetics of a Single Dose of Brexpiprazole Long-acting Injection in Healthy Subjects/Patients With Schizophrenia.

Last checked: Nov 20, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

56

Planned (sponsor's estimate)

Start

Apr 10, 2024

Primary completion

Jun 30, 2026

Study completion Oct 30, 2026

Sponsor

Sponsor type
Industry
First posted
Nov 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Study to evaluate the safety and tolerability of single ascending doses of brexpiprazole long-acting injection in healthy subjects/patients with schizophrenia.

Conditions

  • Schizophrenia Disorders

Interventions

  • Brexpiprazole long-acting injectionDrug

    A single injection was administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of reported Adverse Events (AE)Time frame: Collected from signing of informed consent until 90 days after a single dose.
  2. Clinical Laboratory TestsTime frame: Collected from signing of informed consent until 90 days after a single dose.
  3. Change in physical exam resultsTime frame: Collected from signing of informed consent until 90 days after a single dose.
  4. Vital signsTime frame: Collected from signing of informed consent until 90 days after a single dose.
  5. ECG ReadingTime frame: Collected from signing of informed consent until 90 days after a single dose.
  6. Extrapyramidal Symptoms (EPS) Rating ScaleTime frame: Collected from signing of informed consent until 90 days after a single dose.
  7. Change in Suicidality via Columbia-Suicide Severity Rating ScaleTime frame: Collected from signing of informed consent until 90 days after a single dose.
  8. Injection site assessmentTime frame: Collected from signing of informed consent until 90 days after a single dose.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Anding Hospital Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.